Iterum Therapeutics (NASDAQ: ITRM) is one of 548 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its peers? We will compare Iterum Therapeutics to related businesses based on the strength of its earnings, valuation, dividends, institutional ownership, risk, analyst recommendations and profitability.
This table compares Iterum Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Iterum Therapeutics Competitors||-1,760.46%||-120.17%||-28.09%|
This is a summary of recent ratings for Iterum Therapeutics and its peers, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Iterum Therapeutics Competitors||4546||13021||27670||994||2.54|
Iterum Therapeutics presently has a consensus target price of $20.75, suggesting a potential upside of 153.67%. As a group, “Pharmaceutical preparations” companies have a potential upside of 58.45%. Given Iterum Therapeutics’ stronger consensus rating and higher probable upside, equities analysts clearly believe Iterum Therapeutics is more favorable than its peers.
Valuation and Earnings
This table compares Iterum Therapeutics and its peers gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Iterum Therapeutics||$870,000.00||-$77.06 million||-1.15|
|Iterum Therapeutics Competitors||$2.15 billion||$228.73 million||-3.52|
Iterum Therapeutics’ peers have higher revenue and earnings than Iterum Therapeutics. Iterum Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Institutional and Insider Ownership
45.2% of Iterum Therapeutics shares are held by institutional investors. Comparatively, 46.3% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 14.9% of shares of all “Pharmaceutical preparations” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Iterum Therapeutics beats its peers on 7 of the 12 factors compared.
About Iterum Therapeutics
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing anti-infectives for multi-drug resistant pathogens in Ireland and the United States. The company is developing sulopenem, a penem anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of adults in uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. Iterum Therapeutics plc was founded in 2015 and is headquartered in Dublin, Ireland.
Receive News & Ratings for Iterum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iterum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.